Efter 104 ugers behandling var 14 af 21 patienter i live (66, 7%), og 1 patient var i live, men var trådt ud af forsøget.
After 104 weeks of treatment, 14 of 21 patients (66.7%) were alive and 1 patient was alive but had discontinued from the study.